Osteoarthritis News and Research

Latest Osteoarthritis News and Research

Convergence initiates CNV2197944 Phase I study in chronic pain

Convergence Pharmaceuticals Limited, the company focused on the development of novel and high value analgesic medicines, today announced that the first-time-in-man Phase I study of the novel, first in class calcium channel blocker CNV2197944, for the treatment of chronic pain has been initiated and dosing has begun.

22 Apr 2011

Nuvo Research to acquire ZARS Pharma

Nuvo Research Inc., a pharmaceutical company dedicated to building a portfolio of products primarily for the treatment of pain, today announced that it has entered into an agreement to acquire ZARS Pharma, Inc., a specialty pharmaceutical company based in Salt Lake City, Utah.

18 Apr 2011

Blue Cross launches 'The Human Do.ing' project to improve communities' health

He danced. He grooved. He walked. He sweated. And in the end, he did something he wasn't sure was possible. He got healthy. On Saturday, Twin Cities man Scott Jorgenson, 45, ended his 30 days as "The Human Do.ing," a project developed by Blue Cross and Blue Shield of Minnesota as part of the company's do. Campaign to "groove your body every day" to achieve better health.

18 Apr 2011

Researchers report injectable gel can help treat arthritis

Some 25 million people in the United States alone suffer from rheumatoid arthritis or its cousin osteoarthritis, diseases characterized by often debilitating pain in the joints. Now researchers at Brigham and Women's Hospital report an injectable gel that could spell the future for treating these diseases and others.

15 Apr 2011

Study: Simple illusion can reduce arthritic pain

A serendipitous discovery by academics at The University of Nottingham has shown that a simple illusion can significantly reduce — and in some cases even temporarily eradicate — arthritic pain in the hand.

15 Apr 2011

Singing reduces blood pressure prior to total knee replacement surgery

Doctors report that singing reduced the blood pressure of a 76-year-old woman who had experienced severe preoperative hypertension prior to total knee replacement surgery for osteoarthritis (OA). While the patient was unresponsive to aggressive pharmacologic interventions, the woman's blood pressure dropped dramatically when she sang several religious songs.

30 Mar 2011

Orthopedic surgeons prefer Genzyme's 3-cycle hyaluronic-acid in the U.S., Europe

According to a comprehensive global survey of orthopedic surgeons conducted by iData Research, the leading authority in medical device and pharmaceutical market research, orthopedic surgeons prefer 3-cycle hyaluronic-acid viscosupplementation treatment in the U.S., Europe and Latin Ameica, but are willing to try single-injection products such as Synvisc-One from Genzyme and MONOVISC from Anika Therapeutics.

30 Mar 2011

USPTO grants composition-of-matter patent to Zalicus 'Synavive' product

Zalicus Inc. announced today that it has been granted a composition-of-matter patent by the U.S. Patent and Trademark office covering its product candidate Synavive.

30 Mar 2011

People with arthritis can benefit from exercise

An estimated 50 million adults in the United States suffer from arthritis. According to the Centers for Disease Control, one of the best ways to combat the onset of arthritis as well as to control pain and improve function is through exercise.

29 Mar 2011

Artimplant's Artelon CMC Soft receives European CE-mark approval

In collaboration with Small Bone Innovations, Artimplant has developed a new product in the Artelon Spacer range with a similar user-friendly textile design to Artelon Tissue Reinforcement.

28 Mar 2011

$Osteoporotic hip and vertebral fractures have most serious impact on quality of life$

Osteoporotic hip and vertebral fractures have most serious impact on quality of life

A study presented today at the European Congress on Osteoporosis and Osteoarthritis currently taking place in Valencia, Spain has found that the initial quality of life loss following an osteoporotic fracture is substantial, especially with regard to hip and vertebral fractures. The study found differences in quality of life loss between countries after correcting for other explanatory variables.

25 Mar 2011

$Obese postmenopausal women as likely to fracture as non-obese women$

Obese postmenopausal women as likely to fracture as non-obese women

Obesity is widely believed to be protective against fracture, although a recent study has documented a high prevalence of obesity in postmenopausal women with fragility fracture.

25 Mar 2011

Positive Phase 3 results from Tarsa's ORACAL study validates Unigene's oral peptide drug delivery technology

Unigene Laboratories, Inc. a leader in the design, delivery, manufacture and development of peptide-based therapeutics announced today that the statistically significant top-line results released by its licensee, Tarsa Therapeutics, validate its proprietary oral peptide drug delivery technology.

25 Mar 2011

Osteoporosis study: Protelos have significant bone-forming activity than bisphosphonates

Protelos has significantly greater bone-forming activity than the commonly prescribed bisphosphonate, alendronate, according to results of the largest-ever biopsy study in post-menopausal women presented today at the European Congress on Osteoporosis and Osteoarthritis in Valencia.

25 Mar 2011

$Falls history improves accuracy of fracture prediction models$

Falls history improves accuracy of fracture prediction models

Researchers from the MRC Lifecourse Epidemiology Unit in Southampton, UK, have presented a new study that shows how the inclusion of falls history, in addition to clinical risk factors (CRFs) and bone mineral density (BMD) values, would greatly improve the accuracy of fracture prediction models. The research findings were presented today at the European Congress on Osteoporosis & Osteoarthritis in Valencia, Spain.

25 Mar 2011

$ECCEO11-IOF: Total fragility fracture cost in six European countries estimated to be 31 billion Euro$

ECCEO11-IOF: Total fragility fracture cost in six European countries estimated to be 31 billion Euro

Research presented today at the European Congress on Osteoporosis & Osteoarthritis by investigators from the UK and Sweden estimates that the economic burden of fragility fractures in five major European countries totals 31 billion Euro, with Germany bearing the highest costs.

25 Mar 2011

New findings may make morphine a safer, more effective drug for chronic pain control

An orphan drug originally used for HIV treatment has been found to short-circuit the process that results in additional sensitivity and pain from opioid use. The study by researchers at the Indiana University School of Medicine is reported in the March 25, 2011 issue of Brain, Behavior and Immunity.

25 Mar 2011

Experts to present latest advances in bone research at annual European meeting

Today, the European Congress on Osteoporosis and Osteoarthritis opened in Valencia, Spain with some 4000 international participants. The Congress is the major annual European meeting in the bone field and attracts clinicians, specialists and bone experts from around the world. ECCEO11-IOF continues until March 26th at Valencia's Palacio de Congresos.

24 Mar 2011

Prolia associated with greater adherence than alendronate in postmenopausal women with osteoporosis

Amgen today announced new data that showed postmenopausal women with osteoporosis had significantly greater adherence, compliance, and persistence during Prolia® (denosumab) treatment than during alendronate treatment, an oral bisphosphonate commonly used to treat osteoporosis.

24 Mar 2011

New research can lead to better OA treatment

Arthritis researchers from North America and Europe will convene in Chicago this week to present new osteoarthritis research that could lead to better ways to detect, treat, prevent and cure osteoarthritis, which affects 27 million Americans.

24 Mar 2011